Semaglutide vs Tirzepatide: Mechanism & Dosing Compared
Understanding 1.7mg Wegovy vs Mounjaro Mechanisms
The fundamental difference between 1.7mg Wegovy and Mounjaro lies in their receptor targeting approach. Wegovy contains semaglutide, a selective GLP-1 receptor agonist that mimics the natural incretin hormone responsible for appetite regulation and glucose homeostasis. Mounjaro utilises tirzepatide, a dual GIP and GLP-1 receptor agonist, targeting two distinct pathways involved in metabolic regulation. This dual mechanism may provide different satiety profiles and metabolic effects, though both medications work primarily through appetite reduction and delayed gastric emptying. Your prescriber can evaluate which mechanism aligns best with your metabolic profile and treatment response patterns.
At the 1.7mg Wegovy stage, you're approaching peak dosing intensity before transitioning to 2.4mg maintenance. Mounjaro's equivalent progression follows a different trajectory, with doses ranging from 2.5mg through to 15mg maximum. Both require careful dose escalation to minimise gastrointestinal side effects, though the titration schedules differ significantly. Understanding these mechanistic differences helps explain why some patients may respond preferentially to one treatment over another, emphasising the importance of individualised prescriber guidance.
Pricing Comparison for 1.7mg Wegovy vs Mounjaro Treatment
EverydayMeds pricing for 1.7mg Wegovy stands at £139.99 per pen, representing excellent value for this penultimate dose stage. Our Elevate Duo bundle combines 1.7mg and 2.4mg Wegovy for £369.99, providing seamless transition to maintenance dosing with convenient single-order fulfilment. Returning customers benefit from the DOSE25 code applied at checkout, whilst new customers use FIRST40 for optimal pricing. Mounjaro pricing follows a different structure reflecting its distinct dosing schedule and pen configuration.
The Consistency 1.7mg bundle offers two pens for £309.99, ideal for patients requiring extended time at this dose level before progression. Three-pen options include our Progress Trio (0.5mg, 1mg, 1.7mg) at £369.99 for comprehensive dose escalation planning. Bundle pricing emphasises convenience rather than savings—fewer orders, Reliable Supply continuity, and streamlined cold-chain delivery logistics. Both Wegovy and Mounjaro qualify for next-day temperature-controlled delivery once your prescription receives clinical approval.
Clinical Evidence Supporting 1.7mg Wegovy vs Mounjaro Efficacy
The STEP trial programme demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the landmark STEP 1 study (Wilding et al., NEJM, 2021). The 1.7mg dose represents a critical escalation point where many patients begin experiencing enhanced appetite suppression and meaningful weight reduction. STEP 5 confirmed sustained efficacy with clinically studied weight loss maintained at two years, highlighting the importance of long-term treatment commitment.
Mounjaro's clinical evidence stems from the SURMOUNT trial series, though direct head-to-head comparisons remain limited due to different trial designs and patient populations. Both medications require prescription-only access following comprehensive clinical assessment. The SELECT cardiovascular outcomes trial demonstrated Wegovy's additional benefits beyond weight management, with 20% reduction in major cardiovascular events providing compelling evidence for metabolic health improvement.
How Wegovy's GLP-1 Mechanism Delivers Results
Wegovy functions as a GLP-1 receptor agonist, mimicking the natural incretin hormone that regulates appetite and glucose metabolism. Upon injection, semaglutide binds to GLP-1 receptors in the brain's appetite centres, particularly the hypothalamus, reducing hunger signals and promoting satiety after smaller meals. The medication also slows gastric emptying, prolonging the feeling of fullness and reducing the frequency of eating episodes. This dual approach—central appetite suppression combined with delayed stomach emptying—creates a powerful synergy for sustainable weight management. Clinical studies indicate that many patients experience reduced food cravings and find it easier to maintain portion control throughout their treatment journey. The once-weekly injection schedule provides consistent therapeutic levels, supporting steady appetite regulation rather than the fluctuations associated with daily medications.
Streamlined Ordering Process for Both Medications
EverydayMeds' clinical assessment takes just three minutes to complete online, covering medical history, current medications, and weight management goals. Our GPhC-registered prescribers review applications within three working days as standard, with express 24-hour review available for urgent requirements. The assessment determines suitability for either Wegovy or Mounjaro based on individual clinical factors and previous treatment responses. Once approved, your prescription moves to our cold-chain fulfilment centre for next-day temperature-controlled delivery. All shipments include insulated packaging with temperature monitoring to ensure medication integrity throughout transport. Our clinical team remains available for ongoing support throughout your treatment journey, providing medication guidance and addressing any concerns that arise.
Storage and Practical Considerations for Daily Use
Wegovy requires refrigerated storage at 2-8°C before first use, but offers a significant practical advantage with six weeks of room temperature stability once removed from refrigeration. This extended room temperature window exceeds Mounjaro's 21-day limit, providing greater flexibility for travel, work schedules, and lifestyle management. The FlexTouch pen system delivers precise 1.7mg doses with clear visual confirmation and user-friendly operation. Dose escalation remains mandatory—patients cannot skip from 1mg directly to 2.4mg without the intermediate 1.7mg stage. Weekly injection timing should remain consistent, though minor variations (±1 day) are acceptable if needed. Proper injection technique training is provided with every order, including site rotation guidance to minimise injection site reactions.
Comparing 1.7mg Wegovy vs Mounjaro for Long-term Planning
The 1.7mg Wegovy dose represents a crucial transition point where treatment efficacy typically accelerates noticeably. Many patients report this stage as when appetite suppression becomes most pronounced, making dietary adherence significantly easier. Mounjaro's equivalent stage occurs at different dose points due to its distinct pharmacokinetic profile and dual receptor mechanism. Both medications require long-term commitment, as the STEP trials demonstrated that patients regained approximately two-thirds of lost weight within one year of stopping treatment.
Planning your transition from 1.7mg to maintenance dosing involves careful consideration of response patterns, tolerability, and lifestyle factors. EverydayMeds' Elevate Duo provides the perfect bridge from 1.7mg to 2.4mg maintenance, ensuring supply continuity during this critical transition period. Your prescriber can adjust timing based on individual response and any emerging side effects. Both Wegovy and Mounjaro work most effectively alongside a reduced-calorie diet and increased physical activity, representing comprehensive lifestyle interventions rather than standalone solutions.
Expert Support and Prescription-Only Access
Both Wegovy and Mounjaro remain prescription-only medicines requiring clinical oversight throughout treatment. EverydayMeds' qualified prescribers evaluate each application against MHRA-approved criteria, ensuring appropriate patient selection and ongoing safety monitoring. Our clinical team provides comprehensive medication counselling, including injection technique training, side effect management, and dose progression guidance. Returning customers benefit from streamlined reordering with DOSE25 discount codes, whilst maintaining full clinical oversight for safety and efficacy monitoring. Both treatments are available from EverydayMeds with identical service standards—your prescriber can help determine which medication aligns best with your metabolic profile and treatment goals. Contact our clinical team for personalised guidance on navigating the 1.7mg Wegovy vs Mounjaro decision, ensuring optimal outcomes for your weight management journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
